Drugs / Ceftriaxone
Ceftriaxone
also known as
Ceftriaxone sodium · Rocephin · Ceftriaxon · CTX · Cefraden · Ceftriaxona · Ceftriaxone (as sodium) · Ceftriaxone disodium salt · +14 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ROCEPHIN KIT | — | 1984-12-21 | fda.gov ↗ |
Trials 86 · started per year
today
US approved 1984
1
1
1
2
2
1
1
2
2
4
1
2
2
1
2
3
8
4
4
2
4
2
8
3
3
8
4
6
1
1984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04977882 | Oct 2020 → Aug 2022 | colon carcinoma | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT03895567 | Dec 2026 | — | University of Oxford | Suspended | No outcome recorded Stop: Business |
| Phase 1 | NCT05724628 | Oct → Nov 2023 | appendicitis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT00493220 | Jun → Sep 2007 | — | Baxter Healthcare Corporation | Completed | Met primary |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06785402 | May 2026 | post-treatment Lyme disease syndrome | Hackensack Meridian Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02473640 | Jun 2015 → Apr 2016 | — | Theriva Biologics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02419001 | Mar → Sep 2015 | — | Theriva Biologics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00591318 | Oct 2007 → Mar 2011 | schizoaffective disorder, schizophrenia | Research Foundation for Mental Hygiene, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 214 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07485010 | Apr 2027 → Apr 2031 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06406114 | May 2025 → Jul 2028 expected | anaphylaxis, drug allergy, drug pseudoallergy | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05470517 | Jan 2023 → Feb 2024 | appendicitis | Johns Hopkins All Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05375240 | Jun 2022 → Jun 2024 | ischemic stroke | Tianjin Medical University General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05149287 | Dec 2021 → Apr 2022 | articular cartilage disorder | Austin V Stone | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04999592 | Aug 2021 → Mar 2024 | cardiac arrest, pneumonia | David J. Gagnon | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT05216744 | Jul 2021 → Feb 2022 | chlamydia trachomatis infectious disease, gonorrhea | Haiphong University of Medicine and Pharmacy | Completed | Met primary |
| Phase 2 | NCT03794765 | Apr 2019 → Mar 2020 | ulcerative colitis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | Missed primary |
| Phase 2 | NCT03413384 | Feb 2019 → Jul 2025 overdue | Parkinson disease | BrainX Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03681431 | Apr 2018 → Apr 2019 | infective endocarditis | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 2 | NCT02746276 | Apr → Sep 2016 | protein-energy malnutrition | University of Oxford | Unknown | No outcome recorded |
| Phase 2 | NCT00512616 | Aug 2007 → Sep 2009 | bipolar disorder | National Institute of Mental Health (NIMH) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00451386 | Jan 2002 → Dec 2003 | bacterial pneumonia, urinary tract infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00037479 | Dec 1999 → ? | Lyme disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06527989 | Sep 2024 → Sep 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05051163 | Jun 2021 → Jun 2024 | HIV infectious disease, protein-energy malnutrition | Makerere University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02561442 | Oct → Dec 2015 | — | scPharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 318 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT06572761 | Sep 2026 → May 2030 expected | cervical incompetence | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07710118 | Jul 2026 → Dec 2028 expected | gonorrhea | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05821478 | May 2025 → Feb 2027 expected | hidradenitis suppurativa | Institut Pasteur | Recruiting | No outcome recorded |
| Phase 3 | NCT05654896 | Nov 2022 → Nov 2023 | — | Nadeem Iqbal | Unknown | No outcome recorded |
| Phase 3 | NCT04041791 | Aug 2019 → Apr 2024 | pneumonia | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT03174236 | Sep 2017 → Jan 2020 | poisoning, protein-energy malnutrition | University of Oxford | Unknown | No outcome recorded |
| Phase 3 | NCT02389036 | May 2017 → Apr 2023 | critical illness polyneuropathy, infectious disease with sepsis | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT02795949 | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | Met primary |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02265406 | Oct 2015 → Jul 2020 | — | Poitiers University Hospital | Completed | Met primary |
| Phase 3 | NCT02142751 | Jul 2014 → Dec 2018 | escherichia coli infection | Andalusian Public Foundation for Health Research in Seville | Completed | Missed primary |
| Phase 3 | NCT03477422 | Jan 2014 → May 2017 | acute pyelonephritis | Venus Remedies Limited | Completed | Met primary |
| Phase 3 | NCT02177994 | Sep 2013 → Aug 2014 | puerperal infection | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01473836 | Nov 2011 → Oct 2012 | infectious peritonitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00372541 | Sep 2006 → Mar 2007 | pneumonia | Makerere University | Completed | No outcome recorded |
| Phase 3 | NCT00189384 | Nov 2003 → Dec 2005 | bacterial infectious disease with sepsis | Aga Khan University | Unknown | No outcome recorded |
| Phase 3 | NCT00481702 | Dec 2001 → Jun 2003 | intestinal infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00161330 | Jun 2000 → Jul 2005 | urinary tract infection | University of Padova | Terminated | No outcome recorded |
| Phase 430 trials · 2 met primary · 1 missed | ||||||
| Phase 4 | NCT07484633 | Apr 2026 → Apr 2028 expected | infectious disease with sepsis | Semmelweis University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06766461 | Jan 2025 → Dec 2026 expected | infectious disease with sepsis | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06423898 | Oct 2024 → Jul 2027 expected | infective endocarditis | Andalusian Public Foundation for Health Research in Seville | Recruiting | No outcome recorded |
| Phase 4 | NCT06494072 | Aug 2024 → May 2028 expected | — | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 4 | NCT06349122 | Aug 2024 → Mar 2027 expected | bacterial vaginosis | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06396078 | Jul 2024 → Dec 2026 expected | preterm premature rupture of the membranes | Ohio State University | Recruiting | No outcome recorded |
| Phase 4 | NCT06220929 | Jan → Dec 2024 | infectious disease with sepsis, liver disorder | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05156437 | Mar 2022 → Oct 2024 | endocarditis | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05079620 | Nov 2021 → Apr 2024 | aspiration pneumonia, aspiration pneumonitis | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04975945 | Aug → Dec 2021 | — | The Grant Medical College & Sir J.J. Group of Hospitals | Withdrawn | No outcome recorded |
| Phase 4 | NCT04218695 | Aug 2020 → May 2021 | cirrhosis of liver | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04056806 | Aug 2019 → Jun 2022 | esophageal varices with bleeding | E-DA Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03012360 | Feb 2018 → Jul 2024 | — | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 4 | NCT03179384 | Jun 2017 → Feb 2019 | acute pyelonephritis | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 4 | NCT02736682 | Sep 2015 → Feb 2016 | puerperal infection | Makerere University | Completed | No outcome recorded |
| Phase 4 | NCT04202068 | Jul 2015 → May 2016 | gonorrhea | Xiangbei Welman Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04066621 | Apr 2015 → Jun 2016 | bacterial urinary tract infection, respiratory tract infectious disorder | Xiangbei Welman Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02224040 | Aug 2013 → Dec 2014 | typhoid fever | Sheba Medical Center | Unknown | Met primary |
| Phase 4 | NCT01745679 | Dec 2012 → Dec 2015 | infectious disorder of the nervous system, meningitis | Nantes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01390623 | Jul 2011 → Jul 2013 | acute pyelonephritis | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 4 | NCT01278017 | Aug 2010 → Jun 2011 | diarrheal disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01247909 | Apr 2010 → Feb 2015 | bacterial meningitis | Kamuzu University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01678365 | Jul 2008 → Oct 2009 | appendicitis | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT01265173 | Apr 2007 → Jun 2018 | cirrhosis of liver | Korea University | Completed | Missed primary |
| Phase 4 | NCT00449800 | Jul 2006 → Mar 2007 | infectious disease with sepsis | Association Pour La Promotion A Tours De La Reanimation Medicale | Unknown | No outcome recorded |
| Phase 4 | NCT00429975 | Aug 2004 → Sep 2005 | streptococcal pneumonia | Hospital Mutua de Terrassa | Terminated | No outcome recorded |
| Phase 4 | NCT00157898 | Jan → Aug 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00035347 | Jan 2001 → Jun 2002 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00374959 | Oct 2000 → Oct 2003 | pneumonia | Hospital Universitario Principe de Asturias | Completed | No outcome recorded |
| Phase 4 | NCT01559753 | Jan 1998 → Sep 2002 | — | Centre Hospitalier Universitaire de Besancon | Completed | Met primary |
| Phase not applicable13 trials · 1 met primary · 1 missed | ||||||
| — | NCT07792473 | Sep 2026 → Feb 2027 expected | mouth mucosa disorder | University of Yalova | Not yet recruiting | No outcome recorded |
| — | NCT07030673 | Feb 2025 → Mar 2027 expected | viral infectious disease | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| — | NCT06532409 | Oct 2024 → Sep 2025 overdue | pneumonia | RESnTEC, Institute of Research | Not yet recruiting | No outcome recorded |
| — | NCT07308457 | Sep 2024 → Jun 2027 expected | infectious disease | Pomeranian Medical University Szczecin | Recruiting | No outcome recorded |
| — | NCT05750966 | Jul 2023 → Apr 2026 | cholangitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT04839653 | May 2021 → Apr 2022 | acute respiratory distress syndrome, bacterial infectious disease, infectious disease with sepsis, pneumonia | MEDSI Clinical Hospital 1, ICU | Unknown | No outcome recorded |
| — | NCT04935515 | Apr → May 2021 | COVID-19 | Manimarane Arjunan, MD,DM (Cardiology) | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT02996656 | Dec 2016 → Dec 2026 expected | bacterial infectious disease | University of Montreal | Recruiting | No outcome recorded |
| — | NCT02334124 | Jan 2015 → Jun 2017 | cellulitis | Murdoch Childrens Research Institute | Completed | Met primary |
| — | NCT01988428 | Jun 2014 → Jun 2017 | infectious disease with sepsis | Amsterdam UMC, location VUmc | Completed | Missed primary |
| — | NCT00002052 | — | HIV infectious disease, salmonellosis | University of Southern California | Completed | No outcome recorded |
| — | NCT00000648 | ? → Feb 1996 | HIV infectious disease, neurosyphilis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy106 trials | ||||||
| Phase 0 | NCT06611111 Comparator | Feb 2025 → Dec 2026 expected | post-treatment Lyme disease syndrome | State University of New York - Upstate Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT05761405 Comparator | Jan 2024 → Oct 2025 | urinary tract infection | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 0 | NCT05849090 Comparator | Mar 2023 → Dec 2024 | infectious disease | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Show all 106 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-03 | Basilea Pharmaceutica | Results Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 basilea.com ↗
Using the FDA-CABP-2020 primary endpoint of early clinical success at day 3 after study start, this re-analysis supported the non-inferiority of ceftobiprole to ceftriaxone ± linezolid. |
| 2016-05-16 | Theriva Biologics, Inc. | Results Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea therivabio.com ↗
In addition, ceftriaxone plasma concentrations in study participants were very similar in the presence or absence of an oral PPI. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-03 | Basilea Pharmaceutica | Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 basilea.com ↗ |
| 2016-05-16 | Theriva Biologics, Inc. | Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea therivabio.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 199 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftriaxone | “Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ...” NCT02389036 ↗184“Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗ “Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until...” NCT02515565 ↗ “The intravenous-group will receive Beta-lactam antimicrobials (i.e Piperacillin-Tazobactum 4.5g q 8 hourly or Ceftriaxone 1g q 12 hourly or Meropenem 1g q 8 hourly or...” NCT06847126 ↗ “empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗ “The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem,...” NCT04879030 ↗ “A combined oral care solution containing 40 mg methylprednisolone, 1000 mg ceftriaxone, and 0.84 g sodium bicarbonate will be used as a topical oral care intervention.” NCT07792473 ↗ “Ceftriaxone infusion. Ceftriaxone is a beta-lactam antibiotic that is the standard-of-care antibiotic for prophylaxis of asymptomatic bacteriuria in Switzerland.” NCT05761405 ↗ “Commonly used intravenous antibiotics (and doses) for treatment of Gram-negative bacteraemia include ceftriaxone 2 g daily or cefazolin 2 g three times daily.” NCT05199324 ↗ “Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days.” NCT05544565 ↗ “standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin/clavulanic acid,” PMID 40119275 ↗ Mar 2025 |
| Known as | Cefraden | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxon | “* Ceftriaxon : 1g to 2g/day in IV, IM or SC” NCT05074147 ↗ |
| Known as | Ceftriaxona | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone (as sodium) | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone disodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone disodium salt hemiheptahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone sodium | “Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured,...” NCT03675178 ↗10“Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is...” NCT01473836 ↗ “Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously.” NCT00195351 ↗ “Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously.” NCT00230971 ↗ “Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection.” NCT00644150 ↗ “Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).” NCT03895567 ↗ “Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days” NCT00451386 ↗ “Ceftriaxone sodium and Sulbactam Sodium for injection” NCT04202068 ↗ “Drug: Ceftriaxone Sodium” NCT05051163 ↗ |
| Known as | Ceftriaxone sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone sodium component of rocephin kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone sodium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftriaxone sodium sesquaterhydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Ceftrisol Plus | “Cephalosporin- Ceftriaxone, (Ceftrisol Plus, Rocephin)” NCT05849090 ↗ |
| Known as | CRO | “a single 1 g intravenous (IV) dose of ceftriaxone (CRO) plus doxycycline (DOX) versus a single 800 mg oral dose of cefixime (CFM) plus DOX for the treatment of NG-CT co-infection” PMID 35810277 ↗ Jul 2022 |
| Known as | CTRX | “intravenous MNZ combined with ceftriaxone (CTRX) in Japanese subjects” PMID 25442806 ↗ Nov 2014 |
| Known as | CTX | “In this pilot study, we aimed to assess the feasibility of a randomized study of whether prophylactic ceftriaxone (CTX), administered to hospitalized patients with advanced...” PMID 38180983 ↗ Jan 20242“ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day)” NCT07484633 ↗ “ceftriaxone-metronidazole (CTX/MET)” PMID 22439781 ↗ Mar 2012 |
| Known as | Megion | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | RO 13-9904 | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | RO-13-9904/001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Rocefin | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Known as | Rocephin | “The treatment involves 10 weeks of either intravenous antibiotic called ceftriaxone (also known as Rocephin) or intravenous placebo (inactive substance).” NCT00037479 ↗6“Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used” NCT05398081 ↗ “a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day)” NCT05821478 ↗ “Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).” NCT03895567 ↗ “Cephalosporin- Ceftriaxone, (Ceftrisol Plus, Rocephin)” NCT05849090 ↗ “Ceftriaxone (Rocephin®)” NCT07229755 ↗ “Ceftriaxone (Rocephin®)” NCT06611111 ↗ |
| Known as | Rocephin (ceftriaxone) | “Rocephin (ceftriaxone)” NCT04999592 ↗ |
| Known as | Sodium ceftriaxone, anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗ |
| Action | Activate | “ceftriaxone increases EAAT2 activity” PMID 25297012 ↗ Oct 2014 |
| Modality | Other / unclassified | “cephalosporine : ceftriaxone by intra venous route” NCT00136656 ↗ |
| Route | Intravenous | “Ceftriaxone IV on day 1” NCT00004216 ↗ |